Li Zijian is a researcher at the Institute of Vascular Medicine, Peking University Third Hospital, and a doctoral advisor. He specializes in cardiovascular pharmacology, molecular pharmacology, and clinical pharmacology. Dr. Li is the chief scientist of the National Natural Science Foundation's major vascular research program and the principal investigator of a key international cooperation project under the same foundation. His primary research focuses on cardiovascular receptors and diseases, as well as clinical cardiovascular pharmacology. Dr. Li has published over 100 SCI papers in various journals, including sub-journals of Cell, Trends in Pharmacological Sciences, Nature, The FASEB Journal, European Heart Journal, Journal of Biological Chemistry, Cell Research, and British Journal of Pharmacology. As a project leader, he has overseen 18 national projects at various levels, including eight major and key projects under the National Natural Science Foundation, as well as "973" projects and major new drug creation initiatives. Dr. Li holds six authorized national invention patents as the first inventor and has received three provincial and ministerial first-class scientific and technological progress awards. |
